New pill could cut recurrence risk in aggressive breast cancer
NCT ID NCT04254263
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding the drug pyrotinib to standard trastuzumab therapy can lower the risk of cancer coming back in women with HER2-positive breast cancer who still have cancer cells after initial treatment. About 316 women will take pyrotinib daily for a year. Researchers will track how long participants stay cancer-free and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pyrotinib (a targeted cancer drug taken as a pill once daily for one year, combined with trastuzumab)
What this could lead to
If successful, this could offer a new option to lower the chance of breast cancer returning in patients who still have cancer cells after initial chemotherapy and targeted therapy.
What could go wrong
This is a phase 3 trial, but it is still recruiting and results are not yet known. The drug may cause side effects, and it is unclear if it will be more effective than current standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact Email: •••••@•••••